BMS Announces Three AI Drug Discovery Deals in One Day, Committing Nearly $7.5 Billion

BMS closed three AI drug discovery collaborations in a single day, committing nearly $7.5 billion. On October 23, Pathos announced a $237 million Series E round led by BMS with existing investors participating, at a post-money valuation of about $3 billion. BMS will also partner with Pathos and Tempus, targeting neurological diseases including Alzheimer's disease.